Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest for themselves (or their spouses/partners) that have been resolved through a peer review process: Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Margaret Peng, Lilliam Sklaver Poltorack, PharmD, Ginelle Suarez, Chris Thomson MD, MS, Erin Wall and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc and Genentech BioOncology. Research To Practice receives education grants from Abraxis Oncology, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Genentech BioOncology/OSI Pharmaceuticals Inc, Genomic Health Inc, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.

In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:

Dr Budd — Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic Foundation, Cleveland, Ohio. Consulting Fees: Amgen Inc, Exagen Diagnostics, Pfizer Inc; Contracted Research: Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Immunicon Corporation, Johnson & Johnson Pharmaceuticals, Pfizer Inc, Wyeth. Dr Chlebowski — Professor of Medicine, David Geffen School of Medicine at UCLA; Chief, Medical Oncology, Harbor-UCLA Medical Center, Torrance, California. Consulting Fees: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Novartis Pharmaceuticals, Pfizer Inc, Sanofi-Aventis; Grant Support: Amgen Inc. Dr Geyer — Director of Medical Affairs, National Surgical Adjuvant Breast and Bowel Project; Director of Breast Medical Oncology, Allegheny General Hospital, Pittsburgh, Pennsylvania. Consulting Fees: Genentech BioOncology. Dr Gradishar — Director, Breast Medical Oncology; Associate Professor of Medicine, Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois. Consulting Fees: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Sanofi-Aventis. Dr Henderson — Adjunct Professor of Medicine, University of California, San Francisco, San Francisco, California. Fees for Non-CME Services Received Directly from Commercial Interest or their Agents: Abraxis Oncology; Contracted Research: Abraxis Oncology; Ownership Interest: Johnson & Johnson Pharmaceuticals. Dr Hudis — Chief, Breast Cancer Medicine Service Solid Tumor Division, Memorial Sloan-Kettering Cancer Center, New York, New York. Consulting Fees: Amgen Inc, Bristol-Myers Squibb Company, Novartis Pharmaceuticals, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis; Fees for Non-CME Services Received Directly from Commercial Interest or their Agents: AstraZeneca Pharmaceuticals LP, Genentech BioOncology; Ownership Interest: Genomic Health Inc. Dr O’Shaughnessy — Co-Director, Breast Cancer Research Program, Baylor-Charles A Sammons Cancer Center, US Oncology, Dallas, Texas. Consulting Fees: Abraxis Oncology, Pfizer Inc, Roche Laboratories Inc; Fees for Non-CME Services Received Directly from Commercial Interest or their Agents: Abraxis Oncology, Roche Laboratories Inc, Sanofi-Aventis. Dr Ravdin — Clinical Professor of Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, Texas. Consulting Fees: AstraZeneca Pharmaceuticals LP, Sanofi-Aventis; Ownership Interest: Adjuvant Inc. Dr Rugo — Clinical Professor of Medicine, Carol Franc Buck Breast Care Center; Co-director, Breast Oncology Clinical Trials Program, University of California, San Francisco Comprehensive Cancer Center, San Francisco, California. Fees for Non-CME Services Received Directly from Commercial Interest or their Agents: Amgen Inc; Contracted Research: Genentech BioOncology, Sanofi-Aventis. Dr Tripathy — Professor of Internal Medicine; Director, Komen UT Southwestern Breast Cancer Research Program, University of Texas Southwestern Medical Center, Dallas, Texas. Consulting Fees: Genentech BioOncology, Roche Laboratories Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Roche Laboratories Inc. Dr Wolff — Associate Professor of Oncology, Breast Cancer Program, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland. Contracted Research: Roche Laboratories Inc.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.